Palladium(I) Dimeric Complexes for Antitumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy agents like cisplatin have limitations due to nephro- and neuro-toxicity and inefficacy against certain tumor types, with palladium compounds facing issues of rapid hydrolysis and speciation problems, while palladium(I) complexes have been understudied for their antitumor properties.
Innovation Solution
Development of palladium(I) complexes with heterocyclic units, specifically imidazolidines and benzimidazolidines, which form dimeric species with direct Pd-Pd bonds, stabilized by N-heterocyclic carbenes, and a process for their synthesis involving reaction with palladium(II) complexes to produce compounds with antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If palladium compounds are used as chemotherapy agents, then water solubility and alternative DNA targeting are improved, but hydrolysis speed increases causing ligand dissociation and speciation problems
Solution Approach 1:
The patent combines palladium metal center with N-heterocyclic carbene ligands to create a composite complex structure. The NHC ligands are strongly anchored to the Pd(II) center through covalent bonding, forming a stable composite material that maintains structural integrity in aqueous environments while preventing unwanted hydrolysis and speciation
Solution Approach 2:
The patent changes the chemical parameters of the ligand system by introducing N-heterocyclic carbenes with specific electronic and steric properties. These parameter changes in ligand design (electron-donating groups, steric bulk) directly affect the stability of the Pd complex, reducing hydrolysis speed while maintaining water solubility through appropriate substituent selection
2Adaptability or versatility
If palladium(I) complexes are developed for antitumor activity, then new therapeutic mechanisms are explored, but stability in solid state and solution deteriorates due to sensitivity to oxygen and water
Solution Approach 1:
The patent employs inert atmosphere techniques during synthesis and handling of Pd(I) complexes to prevent oxidation by oxygen. The use of inert solvents and exclusion of moisture during preparation maintains the sensitivity of Pd(I) species while enabling their characterization and evaluation for antitumor activity
Solution Approach 2:
The patent uses ancillary ligands as intermediaries that bridge the Pd(I) metal centers and provide protective coordination. These ligands act as mediators that stabilize the electron-deficient Pd(I) state while allowing the complex to maintain its unique antitumor mechanism through controlled interaction with biological targets
3Stability of the object's composition
If N-heterocyclic carbene ligands are used with Pd(II), then ligand dissociation is reduced, but synthesis complexity increases
Solution Approach 1:
The patent employs preliminary action by pre-synthesizing the N-heterocyclic carbene ligands before complex formation. The ligands are prepared in advance with the appropriate electronic and steric properties, then directly coordinated to Pd(II) centers in a single step, simplifying the overall synthesis while ensuring optimal ligand-metal matching for maximum stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The palladium(I) complexes demonstrate significant antitumor activity against both cisplatin-sensitive and resistant tumor lines with reduced toxicity, showing promise in treating ovarian, cervical, colon, and lung cancers with minimal impact on normal cells.
Implementation Method 1
reacting a compound of general formula (C) or of general formula (D) with a palladium (II) complex... to produce compounds with antitumor activity
Implementation Method 2
dimeric species with direct Pd-Pd bonds
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to a new class of dimeric palladium complexes, wherein the element has oxidation status +1, useful as chemotherapy compounds for treating tumours.